8-K: Septerna Inks $2.2 Billion Deal with Novo Nordisk, Advances Pipeline

Septerna announces a major collaboration with Novo Nordisk potentially worth $2.2 billion and reports its first quarter 2025 financial results, highlighting progress in its GPCR-targeted programs.

Summary

• Septerna, Inc. announced a global collaboration with Novo Nordisk to develop oral small molecules for metabolic diseases, potentially worth over $2.2 billion.
• The collaboration will initially focus on four R&D programs targeting GPCRs, including GLP-1, GIP, and glucagon receptors.
• Septerna is eligible to receive over $200 million in upfront and near-term milestone payments, tiered royalties on global net sales, and the option to participate in a worldwide profit-share for one program.
• The company is on track to select a next-generation oral small molecule PTH1R agonist for hypoparathyroidism by the end of 2025.
• A Phase 1 trial for SEP-631, a MRGPRX2 NAM program for mast cell diseases, is expected to begin in the third quarter of 2025.
• Septerna ended the first quarter of 2025 with $398.2 million in cash, cash equivalents, and marketable securities.
• R&D expenses for the quarter were $19.3 million, compared to $13.2 million in the same period last year.
• General and administrative expenses were $6.9 million, compared to $2.7 million in the prior year.
• The net loss for the quarter was $21.5 million, compared to $14.2 million in the first quarter of 2024.

Sentiment

Score: 8

Explanation: The document is positive due to the significant collaboration with Novo Nordisk, strong cash position, and advancement of the pipeline. The increased expenses and net loss are typical for a biotech company at this stage.

Positives

• The collaboration with Novo Nordisk provides significant financial resources and operational flexibility.
• The $2.2 billion deal with Novo Nordisk validates Septerna's GPCR Native Complex Platform.
• The company is advancing its wholly owned pipeline, including the next-generation oral small molecule PTH1R agonist.
• Septerna has a strong balance sheet with $398.2 million in cash, cash equivalents, and marketable securities.
• The company is on track to select a development candidate for its PTH1R program by the end of 2025.

Negatives

• The net loss for the quarter was $21.5 million, higher than the $14.2 million loss in the same period last year.
• R&D expenses increased to $19.3 million from $13.2 million year-over-year.
• General and administrative expenses increased to $6.9 million from $2.7 million year-over-year.

Risks

• There are uncertainties related to achieving future research, development, and commercial milestones under the Novo Nordisk collaboration.
• There are risks associated with Septerna's product candidates entering clinical trials.
• Unexpected safety or efficacy findings in clinical development could impact the programs.
• The results of preclinical studies may not be predictive of future results in clinical studies.
• Septerna's ability to protect its intellectual property rights is a risk factor.

Future Outlook

Septerna expects the upfront payment from the Novo Nordisk collaboration to significantly extend its prior cash runway guidance of early 2028 and plans to provide updated guidance following the closing of the collaboration agreement. The company also plans to select a next-generation PTH1R product candidate to accelerate toward the clinic later this year and initiate a Phase 1 clinical trial for SEP-631 in the third quarter of this year.

Management Comments

• Yesterday's landmark partnership announcement with Novo Nordisk to advance our incretin programs is an important validation of our GPCR Native Complex Platform and its potential to address major unmet needs in metabolic disease, said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna.
• This collaboration provides a significant opportunity to create multiple potentially groundbreaking oral medicines, while also providing Septerna with substantial resources and operational flexibility to advance our diverse portfolio.
• With a strong balance sheet, a differentiated technology platform, and a clear focus on execution, we believe we are well positioned to create long-term value for patients and shareholders.

Industry Context

The collaboration with Novo Nordisk highlights the increasing interest in GPCR-targeted therapies for metabolic diseases. Novo Nordisk, a leader in diabetes and obesity treatments, is expanding its portfolio through strategic partnerships. This deal positions Septerna as a key player in GPCR drug discovery.

Comparison to Industry Standards

• The $2.2 billion potential value of the Septerna-Novo Nordisk deal is significant compared to other early-stage biotech collaborations.
• For example, similar deals in the GPCR space, such as those involving structure-based drug design companies like Schrödinger, often involve upfront payments in the tens of millions and potential milestones in the hundreds of millions.
• Septerna's $398.2 million cash position is strong relative to other clinical-stage biotechs, providing a solid foundation for advancing its pipeline.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for long-term value creation through the Novo Nordisk collaboration.
• Employees will have opportunities to work on innovative programs and benefit from the company's growth.
• Patients may benefit from the development of new oral small molecule medicines for metabolic diseases, hypoparathyroidism, and mast cell diseases.
• The collaboration could lead to increased business for suppliers and partners.

Next Steps

• Closing of the collaboration agreement with Novo Nordisk.
• Selection of a next-generation PTH1R agonist candidate by the end of 2025.
• Initiation of a Phase 1 clinical trial for SEP-631 in the third quarter of 2025.
• Advancement of TSHR NAM lead compounds towards selection of a development candidate.
• Providing updated cash runway guidance following the closing of the collaboration agreement.

Key Dates

Keywords

Septerna, Novo Nordisk, GPCR, Metabolic Diseases, Collaboration, PTH1R, SEP-631, MRGPRX2, Clinical Trial, Financial Results